MoonLake enters underwriting agreement for 10M share offering

MoonLake Immunotherapeutics entered an underwriting agreement with Leerink Partners to sell up to 10 million ordinary shares and warrants. This public offering, including an option to purchase additional securities, aims to provide capital for business operations and growth.